Abstract 973P
Background
Fibrolamellar carcinoma (FLC) is a rare subtype of liver cancer that primarily affects young adults and adolescents. The main objective of this study is to evaluate the association between survival outcomes and clinical factors of patients with FLC.
Methods
We retrospectively collected clinicopathologic and treatment outcome data from 88 male and 77 female patients with a pathologic diagnosis of FLC. Median overall survival (OS) was calculated using Kaplan-Meier curves. Log rank test, univariable and multivariable Cox models were applied to evaluate the association between clinical outcomes and patients’ characteristics.
Results
Mean age at diagnosis was 27.4 years (age range: 9, 76), median OS was 42.6 months (95% CI: 36.5, 59.2). 50.3% of patients in our study were AJCC Stage IV at the time of presentation, with 67.5% having vascular invasion at diagnosis. 5% of patients had liver cirrhosis. 68.5% of patients received surgery, including metastasectomy. 30.9% received radiation therapy, and 77.5% received systemic therapy. Combination of 5-fluorouracil and interferon-alpha2 was the most frequently used systemic therapy (83 patients), with 45 patients receiving other forms of chemotherapy. The median OS of patients who underwent surgery was 59.2 months (95% CI [49.51, 89.68]) versus 20.34 months (95% CI [15.37, 26.02] in patients who did not. Of those who did not have surgery, 94.2% (49 patients) had AJCC stage >II. Higher tumor stage(>II) (HR=2.841; 95% CI [1.309, 6.165]), lack of surgery (HR=3.47; 95% CI [2.193, 5.488]) and lack of receipt of radiation therapy (HR=1.685; 95% CI [1.059, 2.68]) were positively associated with worse OS.
Conclusions
We identified prognostic factors in FLC. The associations of receipt of surgery and radiation with prolonged OS suggest that local control and cancer debulking in this disease is paramount.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18